Notice of Proposed Sale · 144
PTC Therapeutics, Inc.
PTCTNASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- PTC THERAPEUTICS, INC.
- Issuer CIK
- 0001070081
- SEC file number
- 001-35969
- Phone
- 9082227000
- Person for whose account securities are to be sold
- STEELE GLENN JR MD PHD
- Relationships to issuer
- Director
- Street
- 500 WARREN CORPORATE CENTER DRIVE
- City
- WARREN
- State / country code
- NJ
- Postal code
- 07059
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common | 12,000 | 781,920.00 | 83,460,802 | 09/30/2026 | NASDAQ | Fidelity Brokerage Services LLC |
Broker / market maker — proposed row 1, entry 1
- Name
- Fidelity Brokerage Services LLC
- Street
- 900 Salem Street
- City
- Smithfield
- State / country code
- RI
- Postal code
- 02917
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common | 09/30/2026 | Stock Option Exercise | Issuer | 12,000 | N | 09/30/2026 | Cash |
Prior-sale reporting
- Nothing to report for the preceding three months
- Y
Notice signature
- Notice date
- 09/30/2026
- Signed
- /s/Wade Moss, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Glenn D. Steele Jr
- Plan adoption dates
- 03/09/2026
Company context
PTC is a global biopharmaceutical company dedicated to the discovery, development and commercialization of clinically differentiated medicines for children and adults living with rare disorders. PTC is advancing a robust and diversified pipeline of transformative medicines as part of its mission to provide access to best-in-class treatments for patients with unmet medical needs. The company’s strategy is to leverage its scientific expertise and global commercial infrastructure to optimize value for patients and other stakeholders.